The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study

The proteasome inhibitor bortezomib has a positive effect on renal function in multiple myeloma (MM) patients with renal impairment (RI).[1][1]–[3][2] This led to an update of the Dutch and international guidelines in 2010, recommending bortezomib as first-line treatment in patients with RI.[1][1